Literature DB >> 2141995

Immunogenicity and cross-reactivity of syngeneic murine melanomas.

C Donawho1, M L Kripke.   

Abstract

Non-melanoma skin cancers induced in mice by chemical carcinogens or ultraviolet radiation are often antigenic but rarely induce cross-protective immunity when tested by in vivo transplantation methods. We wished to determine whether melanocytic skin tumors behave similarly or whether they exhibit cross-reactive antigens in vivo. Three melanomas induced in C3H/HeNCr(MTV-) mice by initiation with ultraviolet radiation and promotion with croton oil or initiation with 7,12-dimethyl-benz[a]anthracene and promotion with 12-O-tetradecanoyl-phorbol-13-acetate or croton oil plus ultraviolet radiation were tested for immunogenicity and cross-reactivity in vivo. The three melanomas were highly immunogenic, and all induced some degree of protection against the other melanomas. Non-melanoma skin cancers induced by the same carcinogens were less immunogenic and did not immunize against the melanomas. We conclude that unlike other skin cancers, melanocytic tumors induced by chemical carcinogens and ultraviolet radiation are highly cross-reactive in vivo and thus represent a unique subset of murine skin cancers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2141995     DOI: 10.3727/095535490820874597

Source DB:  PubMed          Journal:  Cancer Commun        ISSN: 0955-3541


  3 in total

Review 1.  Heat shock proteins: the fountainhead of innate and adaptive immune responses.

Authors:  S Basu; P K Srivastava
Journal:  Cell Stress Chaperones       Date:  2000-11       Impact factor: 3.667

Review 2.  Photoimmunology of experimental melanoma.

Authors:  C K Donawho; M L Kripke
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

3.  Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells.

Authors:  G M Halliday; A Patel; M J Hunt; F J Tefany; R S Barnetson
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.